Phillips Kathryn A, Liang Su-Ying, Van Bebber Stephanie
University of California at San Francisco, Department of Clinical Pharmacy, School of Pharmacy, Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center, San Francisco, CA 94143 USA.
Curr Opin Mol Ther. 2008 Jun;10(3):260-6.
It is important to understand how knowledge of genomics can be translated from research into clinical practice and health policies. This review examines existing evidence on three key factors in the adoption of personalized medicine: utilization, preferences, and economic value, using two cancer examples: HER2/neu antigen testing and trastuzumab (Herceptin) treatment and genetic testing for Lynch syndrome. Our findings highlight areas in which additional research is required to build an evidence base addressing utilization of, preferences for, and the potential costs and benefits of personalized medicine. Major challenges include a lack of linked data, the need for relevant research frameworks and methodologies, and the clinical complexities of genomic-based diagnostics and treatment.
了解基因组学知识如何从研究转化为临床实践和卫生政策非常重要。本综述以两个癌症实例：HER2/neu抗原检测和曲妥珠单抗（赫赛汀）治疗以及林奇综合征的基因检测，审视了关于采用个性化医疗的三个关键因素的现有证据：利用情况、偏好和经济价值。我们的研究结果突出了需要进行更多研究以建立证据基础的领域，该证据基础涉及个性化医疗的利用情况、偏好以及潜在成本和效益。主要挑战包括缺乏关联数据、需要相关研究框架和方法，以及基于基因组的诊断和治疗的临床复杂性。
